UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 38

of '进展期胰腺外分泌癌的化疗'

38
TI
Phase II study of epirubicin in advanced adenocarcinoma of the pancreas.
AU
Wils J, Bleiberg H, Blijham G, Dalesio O, Duez N, Lacave A, Splinter T
SO
Eur J Cancer Clin Oncol. 1985;21(2):191.
 
The EORTC Gastrointestinal Group has conducted a phase II trial in 41 patients with locally advanced or metastatic adenocarcinoma of the pancreas with epirubicin 90 mg/m2 intravenously every 4 weeks, with dose escalation if possible. Seven patients were not evaluable for response. In 34 evaluable patients there were two complete and six partial responses (response rate 24%). Nine patients had stable disease for at least 2 months, including one patient with a minor response. Median time to progression for responders was 7 months, for all patients 3 months. Median survival for responders was 9 months, for all patients 5 months. It is concluded that epirubicin is an active drug in pancreatic cancer.
AD
PMID